AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21258027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy for smoking cessation
Number of subjects: 816
Study 21258027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy for smoking cessation (short-term follow-up ≤ 12 weeks)
Number of subjects: 816
Study 21258027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy for smoking cessation (mid-term follow-up 26 weeks)
Number of subjects: 816
Study 19237436 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise intervention (1 hour per week for 8 weeks)
Number of subjects: 20
Study 19237436 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise-based social and leisure activities (control)
Number of subjects: 20
Study 16773754 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 0
Study 15590048 — intervention group
Group type: EXPERIMENTAL
Intervention: Last Observation Carried Forward (LOCF)
Number of subjects: 0
Study 15590048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignorable Maximum Likelihood (IML)
Number of subjects: 0
Study 15590048 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Imputation (MI)
Number of subjects: 0
Study 15590048 — intervention group
Group type: EXPERIMENTAL
Intervention: Piecewise splines and rescue (treatment adjustment)
Number of subjects: 0
Study 11716885 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit care
Number of subjects: 304
Study 11716885 — intervention group
Group type: COMPARATOR
Intervention: General ward care
Number of subjects: 304
Study 9249123 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 15
Study 8424497 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of glucose mixed with 100 U of human insulin (HI/100)
Number of subjects: 50
Study 8424497 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of glucose mixed with 100 U of bovine insulin (BI/100)
Number of subjects: 50
Study 8424497 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of glucose mixed with 50 U of human insulin (HI/50)
Number of subjects: 50
Study 8424497 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of glucose mixed with 50 U of bovine insulin (BI/50)
Number of subjects: 50
Study 8424497 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 50
Study 8424497 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (all groups)
Number of subjects: 50
Study 3118005 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin/gentamicin
Number of subjects: 29
Study 3118005 — intervention group
Group type: COMPARATOR
Intervention: clindamycin/gentamicin
Number of subjects: 29
Study 29650034 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback about weight-bearing during gait in addition to care as usual
Number of subjects: 188
Study 29650034 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 188
Study 28808030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal delivery of oxytocin paired with peer-derived altruistic norms
Number of subjects: 183
Study 28808030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal delivery of oxytocin
Number of subjects: 183
Study 28808030 — intervention group
Group type: COMPARATOR
Intervention: Participants with higher levels of xenophobia
Number of subjects: 183
Study 25365778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful awareness and acceptance treatment (M)
Number of subjects: 143
Study 25365778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for pain (CBT-P)
Number of subjects: 143
Study 25365778 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis education (E)
Number of subjects: 143
Study 24024323 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbanxiao solution
Number of subjects: 60
Study 24024323 — intervention group
Group type: COMPARATOR
Intervention: Compound Kushen injection
Number of subjects: 60
Study 21401941 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence nurse practitioner (CNP) intervention
Number of subjects: 3746
Study 21401941 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 3746
Study 18416260 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL (Tecnis Z9000)
Number of subjects: 114
Study 18416260 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric diffractive multifocal IOL (Tecnis ZM900)
Number of subjects: 114
Study 18416260 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonal refractive multifocal IOL (ReZoom)
Number of subjects: 114
Study 18416260 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric diffractive multifocal IOL (TwinSet)
Number of subjects: 114
Study 16850289 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 112
Study 16850289 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 112
Study 16850289 — intervention group
Group type: COMPARATOR
Intervention: International Surgical Journals
Number of subjects: 112
Study 12554382 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in a rehabilitation centre in Tenerife for four weeks (Group 1, n=30)
Number of subjects: 88
Study 12554382 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in two similar centres in Norway for four weeks (Group 2, n=29)
Number of subjects: 88
Study 12554382 — intervention group
Group type: COMPARATOR
Intervention: Ordinary health care programme (Control Group 3, n=29)
Number of subjects: 88
Study 11097585 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted flap thickness of 160 micrometer
Number of subjects: 60
Study 11097585 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted flap thickness of 180 micrometer
Number of subjects: 60
Study 11097585 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted flap thickness of 200 micrometer
Number of subjects: 60
Study 11097585 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted tissue ablation
Number of subjects: 60
Study 8865507 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjusting pressure mode
Number of subjects: 12
Study 8865507 — intervention group
Group type: COMPARATOR
Intervention: Standard NCPAP mode
Number of subjects: 12
Study 1371323 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 19
Study 1371323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6388803 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation combined with 5-fluorouracil and methotrexate
Number of subjects: 34
Study 30079583 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 45
Study 30079583 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 45
Study 27417017 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, applied twice daily for 28 days
Number of subjects: 0
Study 27417017 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 24155106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.2 g of elemental calcium in the form of calcium carbonate)
Number of subjects: 1103
Study 24155106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 1103
Study 24155106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (in women taking at least 80% of the supplements)
Number of subjects: 1103
Study 24155106 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium intake (diet and supplements)
Number of subjects: 1103
Study 23518156 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted TIV
Number of subjects: 43802
Study 23518156 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted TIV
Number of subjects: 43802
Study 20350027 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track PATHS curriculum and teacher consultation
Number of subjects: 2937
Study 20350027 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2937
Study 17949683 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐Acceptance
Number of subjects: 80
Study 17949683 — intervention group
Group type: COMPARATOR
Intervention: Full‐Distraction
Number of subjects: 80
Study 17949683 — intervention group
Group type: COMPARATOR
Intervention: Instruction‐only‐Acceptance
Number of subjects: 80
Study 17949683 — intervention group
Group type: COMPARATOR
Intervention: Instruction‐only‐Distraction
Number of subjects: 80
Study 17949683 — intervention group
Group type: COMPARATOR
Intervention: No‐Instructions
Number of subjects: 80
Study 16626610 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart presenting pregnancy risk (continuum ranking)
Number of subjects: 900
Study 16626610 — intervention group
Group type: COMPARATOR
Intervention: Chart presenting pregnancy risk (other 2 charts)
Number of subjects: 900
Study 12644943 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol drops
Number of subjects: 356
Study 12644943 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 356
Study 10861704 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser 1 (9.12 Hz)
Number of subjects: 32
Study 10861704 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser 2 (73 Hz)
Number of subjects: 32
Study 10861704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10861704 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 9175948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1 x 10 mg/kg, followed by 5 mg/kg 24 and 48 hours later
Number of subjects: 40
Study 9175948 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 3 x 0.2 mg/kg at 12 hour intervals
Number of subjects: 40
Study 1493229 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant tone pairs (p=15%)
Number of subjects: 0
Study 1493229 — intervention group
Group type: COMPARATOR
Intervention: Standard tone pairs (p=85%)
Number of subjects: 0
Study 3547369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide (two 1 gm doses)
Number of subjects: 101
Study 3547369 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin (five doses)
Number of subjects: 101
Study 29649021 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization intervention (in-bed cycling)
Number of subjects: 37
Study 27144905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisone (60 mg/day)
Number of subjects: 38
Study 27144905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone (15 mg/day)
Number of subjects: 38
Study 27144905 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose prednisone (30 mg/day)
Number of subjects: 38
Study 27144905 — intervention group
Group type: COMPARATOR
Intervention: Standard HF care alone
Number of subjects: 38
Study 24915838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 425
Study 22460228 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-step counseling (NSC)
Number of subjects: 2000
Study 22460228 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral assessment (NA)
Number of subjects: 2000
Study 21294416 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg noni extract
Number of subjects: 100
Study 21294416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21294416 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg noni extract
Number of subjects: 100
Study 21294416 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg noni extract
Number of subjects: 100
Study 18051010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast Ni‐Cr alloy dowel‐core with no ferrule (Group A1)
Number of subjects: 32
Study 18051010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast Ni‐Cr alloy dowel‐core with 2.0 mm ferrule (Group A2)
Number of subjects: 32
Study 18051010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated carbon fiber‐reinforced dowel‐resin core with no ferrule (Group B1)
Number of subjects: 32
Study 18051010 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber‐reinforced dowel‐resin core with 2.0 mm ferrule (Group B2)
Number of subjects: 32
Study 16042639 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (bup-nx)
Number of subjects: 344
Study 16042639 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 344
Study 10950411 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral diode laser
Number of subjects: 120
Study 10950411 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 120
Study 9287259 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 92
Study 9287259 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 92
Study 8346727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 50
Study 8346727 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 50
Study 3730529 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 15
Study 3730529 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg (innovator dosage form)
Number of subjects: 15
Study 3730529 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg (generic dosage form)
Number of subjects: 15
Study 3730529 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg (solution dosage form)
Number of subjects: 15
Study 3730529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29726071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68-PSMA-11 PET/CT
Number of subjects: 0
Study 29726071 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging (CT of abdomen/pelvis and bone scintigraphy with SPECT/CT)
Number of subjects: 0
Study 29726071 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT
Number of subjects: 0
Study 27661469 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair Yoga (CY)
Number of subjects: 100
Study 27661469 — intervention group
Group type: COMPARATOR
Intervention: Health Education Program (HEP)
Number of subjects: 100
Study 23924290 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) at 0.3 mg/kg twice daily for 2 weeks
Number of subjects: 32
Study 23924290 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study 21590656 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed technique (group A, n=52)
Number of subjects: 104
Study 21590656 — intervention group
Group type: COMPARATOR
Intervention: Open technique (group B, n=52)
Number of subjects: 104
Study 18377134 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent social support intervention
Number of subjects: 226
Study 18377134 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care counseling
Number of subjects: 226
Study 16926668 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise programme (12 weeks)
Number of subjects: 60
Study 16926668 — intervention group
Group type: COMPARATOR
Intervention: Control group (seated, no exercise)
Number of subjects: 60
Study 14668066 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief leaflet
Number of subjects: 172
Study 14668066 — intervention group
Group type: COMPARATOR
Intervention: Extended leaflet
Number of subjects: 172
Study 14668066 — intervention group
Group type: COMPARATOR
Intervention: No leaflet
Number of subjects: 172
Study 14668066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both leaflets
Number of subjects: 172
Study 10867042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 mL/d, 47.1 mg/d lycopene)
Number of subjects: 53
Study 10867042 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 53
Study 9434064 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone + azathioprine + cyclosporin (PAC)
Number of subjects: 0
Study 9434064 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone + cyclosporin (PC)
Number of subjects: 0
Study 9434064 — intervention group
Group type: COMPARATOR
Intervention: prednisolone + azathioprine (PA)
Number of subjects: 0
Study 8104724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) block
Number of subjects: 75
Study 8104724 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal block
Number of subjects: 75
Study 8104724 — intervention group
Group type: COMPARATOR
Intervention: Epidural block
Number of subjects: 75
Study 8104724 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 4.0 mg
Number of subjects: 75
Study 8104724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 75
Study 8104724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.4 mg
Number of subjects: 75
Study 3661279 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to quit given by a smoking physician model
Number of subjects: 54
Study 3661279 — intervention group
Group type: COMPARATOR
Intervention: Advice to quit given by a nonsmoking physician model
Number of subjects: 54
Study 3661279 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to quit
Number of subjects: 54
Study 3661279 — intervention group
Group type: EXPERIMENTAL
Intervention: Model behavior (smoking or nonsmoking)
Number of subjects: 54
Study 29763713 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM33 (33°C)
Number of subjects: 567
Study 29763713 — intervention group
Group type: COMPARATOR
Intervention: TTM36 (36°C)
Number of subjects: 567
Study 29763713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation settings
Number of subjects: 567
Study 29763713 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate
Number of subjects: 567
Study 27009108 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg twice a day for 4 weeks, then 10 μg twice a day)
Number of subjects: 150
Study 27009108 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30
Number of subjects: 150
Study 24748348 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 0
Study 24748348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadaptive working memory training with low memory loads
Number of subjects: 0
Study 24748348 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study 23901094 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily acyclovir 400 mg twice daily
Number of subjects: 911
Study 23901094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study 20141265 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 0
Study 20141265 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychodynamic therapies
Number of subjects: 0
Study 18622273 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 20823824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml/day intravenous for 10 days, then 2 tablets twice a day for 25 days)
Number of subjects: 30
Study 20823824 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only (comparison group)
Number of subjects: 30
Study 15840055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 microg PO daily
Number of subjects: 60
Study 15840055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 60
Study 15840055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin 200 IU every other day
Number of subjects: 60
Study 15840055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 11964564 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐Methylpyrazole (10‐15 mg/kg orally)
Number of subjects: 35
Study 11964564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9548634 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free detention treatment program (DVA)
Number of subjects: 86
Study 9548634 — intervention group
Group type: COMPARATOR
Intervention: Control group (42 male inmates from other wings)
Number of subjects: 86
Study 7846294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin
Number of subjects: 8
Study 7846294 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 8
Study 2850322 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW heparin (Fluxum) at doses of 4,000 or 8,000 I.U. Axa once a day by subcutaneous injection
Number of subjects: 610
Study 2850322 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin at doses of 5,000 I.U. two or three times a day by subcutaneous injection
Number of subjects: 610
Study 31721026 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 1 year
Number of subjects: 164
Study 31721026 — intervention group
Group type: COMPARATOR
Intervention: Control group (other hypoglycemic agents) for 1 year
Number of subjects: 164
Study 31721026 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 164
Study 31721026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 26362578 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 polyunsaturated fatty acids (PUFAs) 1.2 g/day for 12 weeks
Number of subjects: 81
Study 26362578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 26617271 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel 5% vaginal cream (5 g/day for 8 weeks)
Number of subjects: 60
Study 26617271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24725898 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization in abduction and external rotation (AbER, n = 51) with a stabilizer brace
Number of subjects: 102
Study 24725898 — intervention group
Group type: COMPARATOR
Intervention: Immobilization in adduction and internal rotation (AdIR, n = 51) using sling and swathe bandage
Number of subjects: 102
Study 24725898 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization in abduction and external rotation (AbER)
Number of subjects: 102
Study 24725898 — intervention group
Group type: COMPARATOR
Intervention: Immobilization in adduction and internal rotation (AdIR)
Number of subjects: 102